Eli Lilly's (LLY) Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Eli Lilly & Co. (LLY) Raises Quarterly Dividend 15.3% to $0.98; 1.6% Yield
December 13, 2021 3:36 PM ESTEli Lilly & Co. (NYSE: LLY) declared a quarterly dividend of $0.98 per share, or $3.92 annualized. This is a 15.3% increase from the prior dividend of $0.85.
The dividend will be payable on March 10, 2022, to stockholders of record on February 15, 2022, with an ex-dividend date of February 14,... More
Foghorn’s (FHTX) Lilly/Loxo Deal is All-Around Positive, Validates Robust Drug Discovery Engine - Analyst
December 13, 2021 9:59 AM ESTEarlier today, Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform. The collaboration includes a co-development... More
Pre-Open Stock Movers 12/13: (ARNA) (FHTX) (HOG) Higher; (NISN) (TXMD) (AMPE) Lower (more...)
December 13, 2021 9:21 AM ESTPre-Open Stock Movers
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) 86.7% HIGHER; Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7... More
Foghorn Therapeutics Inc. (FHTX) Climbs 37% Following Pact with Eli Lilly & Co. (LLY)
December 13, 2021 6:15 AM ESTFoghorn Therapeutics Inc. (NASDAQ: FHTX) Climbs 37% Following Pact with Eli Lilly & Co. (NYSE: LLY)
... MoreEli Lilly’s (LLY) Loxo and Foghorm (FHTX) Collaborate for Novel Oncology Targets using Foghorn’s Gene Traffic Control Platform
December 13, 2021 6:03 AM ESTLoxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform. The collaboration includes a co-development and co-commercialization agreement for Foghorn's selective BRM oncology program and an additional undisclosed oncology target. In addition, the collaboration includes three additional discovery programs using Foghorn's proprietary Gene Traffic Control platform.
Under the terms of the agreement, Foghorn will receive upfront... More
